The estimated rates of maintaining sinus rhythm at 12 months after the first 3 months were 78 and 72 % , in the flecainide and control groups , respectively ( log-rank P = 0.68 ) , and the rates were 51 and 90 % in those with and without the primary endpoint , respectively ( log-rank P < 0.001 ) .